Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01436422
First received: September 16, 2011
Last updated: February 28, 2014
Last verified: February 2014

September 16, 2011
February 28, 2014
August 2011
May 2014   (final data collection date for primary outcome measure)
  • Safety of two TetraVax-DV admixtures, as assessed by the frequency of vaccine-related adverse events (AEs), graded by severity [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: Yes ]
  • Immunogenicity of two TetraVax-DV admixtures, as assessed by neutralizing antibody titers to DEN1, DEN2, DEN3, and DEN4 [ Time Frame: Measured through Day 180 after each vaccination ] [ Designated as safety issue: No ]
    Monovalent, bivalent, trivalent, and tetravalent seropositivity and seroconversion rates will be determined at 28, 56, and 90 days after each vaccination.
  • Seropositivity in those vaccinees who remained seronegative to one or more DENV serotypes following the first vaccination and who recieved a second dose of vaccine given at Day 180 [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01436422 on ClinicalTrials.gov Archive Site
  • Frequency of viremia following vaccination [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Number of vaccinees infected with DEN1, DEN2, DEN3, and DEN4 [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
    Infection is defined as recovery of vaccine virus from the blood or serum of a participant and/or by seropositivity to DEN virus (PRNT50 greater than or equal to 1:10).
  • Duration of the neutralizing antibody response 26 weeks after each vaccination [ Time Frame: Measured 26 weeks after each vaccination ] [ Designated as safety issue: No ]
  • Ability of a second dose of vaccine to boost serum neutralizing antibody titers by Day 270 [ Time Frame: Measured at Day 270 ] [ Designated as safety issue: No ]
    Boost will be defined as a greater than or equal to 4-fold rise in serum neutralizing antibody titer by Day 270 compared with Day 180.
  • Evaluate the phenotype of peripheral blood mononuclear cells at primary infection with the TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Evaluate the cellular immune response to primary infection with the TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Evaluate the innate immune response to primary infection with the TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Evaluate B and T cell memory responses following primary and secondary infections with TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Quantity of viremia following vaccination [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Duration of viremia following vaccination [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Assess the frequency, quantity, and duration of viremia following vaccination [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Determine the number of vaccinees infected with DEN1, DEN2, DEN3, and DEN4 [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
    Infection is defined as recovery of vaccine virus from the blood or serum of a participant and/or by seropositivity to DEN virus (PRNT50 greater than or equal to 1:10).
  • Duration of the neutralizing antibody response 26 weeks after each vaccination [ Time Frame: Measured 26 weeks after each vaccination ] [ Designated as safety issue: No ]
  • Ability of a second dose of vaccine to boost serum neutralizing antibody titers by Day 270 [ Time Frame: Measured at Day 270 ] [ Designated as safety issue: No ]
    Boost will be defined as a greater than or equal to 4-fold rise in serum neutralizing antibody titer by Day 270 compared with Day 180.
  • Evaluate the phenotype of peripheral blood mononuclear cells at primary infection with the TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Evaluate the cellular immune response to primary infection with the TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Evaluate the innate immune response to primary infection with the TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
  • Evaluate B and T cell memory responses following primary and secondary infections with TetraVax-DV vaccine [ Time Frame: Measured through Day 360 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects

Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses to two formulations of a tetravalent dengue virus vaccine in healthy adults.

Dengue viruses cause dengue fever and the more severe condition, dengue hemorrhagic fever/shock syndrome. Dengue viruses are common in most tropical and subtropical regions of the world and infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries. For these reasons, the World Health Organization (WHO) has made the development of a dengue virus vaccine a top priority. This study will evaluate the safety and immunogenicity of two doses of a live, attenuated, tetravalent dengue virus vaccine called TetraVax-DV in healthy adults. Two different versions of the TetraVax-DV vaccine will be evaluated.

This study will enroll healthy adults 18-50 years old. Participants will be randomly assigned to receive one of two admixtures of the TetraVax-DV vaccine or a placebo. At a baseline study visit, participants will undergo a medical history review, physical examination, blood collection, vital sign measurements, and a pregnancy test for females. Participants will then receive one injection of their assigned vaccine in the upper arm. After receiving the vaccine, participants will remain in the clinic for 30 minutes for observation and monitoring. At home, participants will monitor and record their temperature three times a day for 16 days. Additional study visits will occur at Days 3, 8, 10, 12, 14, 16, 21, 28, 56, 90, and 150 and will include a physical examination, assessment of symptoms, and blood collection. On Day 180, participants will receive a second injection of the same vaccine they received at the baseline study visit. Follow-up study visits will occur at Days 183, 188, 190, 192, 194, 196, 201, 208, 236, 270, and 360, and will include the same study procedures and monitoring that occurred after the first vaccination.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Dengue
  • Biological: TetraVax-DV Vaccine - Admixture TV003
    One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
  • Biological: TetraVax-DV Vaccine - Admixture TV005
    One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
  • Biological: Placebo
    One subcutaneous injection at Day 0 and Day 180 of placebo
  • Experimental: TetraVax-DV Vaccine - Admixture TV003
    Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
    Intervention: Biological: TetraVax-DV Vaccine - Admixture TV003
  • Experimental: TetraVax-DV Vaccine - Admixture TV005
    Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
    Intervention: Biological: TetraVax-DV Vaccine - Admixture TV005
  • Placebo Comparator: Placebo
    Participants will receive the placebo at Day 0 and Day 180.
    Intervention: Biological: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
112
Not Provided
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • In good general health, as determined by physical examination, laboratory screening, and review of medical history
  • Available for the duration of the study, approximately 26 weeks post-vaccination
  • Willing to participate in the study as evidenced by signing the informed consent document
  • Female participants of childbearing potential must be willing to use effective contraception for the duration of the trial. More information on this criterion can be found in the protocol.

Exclusion Criteria:

  • Currently pregnant (as determined by positive beta-human choriogonadotropin [HCG] test) or breastfeeding
  • Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies
  • Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the requirements of the study protocol
  • Screening laboratory values of Grade 1 or above for absolute neutrophil count (ANC), alanine aminotransferase (ALT), and serum creatinine, as defined in the protocol
  • Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
  • Any significant alcohol or drug abuse in the 12 months prior to study entry that has caused medical, occupational, or family problems, as indicated by a participant's history
  • History of a severe allergic reaction or anaphylaxis
  • Severe asthma (emergency room visit or hospitalization within the 6 months prior to study entry)
  • HIV infection, by screening and confirmatory assays
  • Hepatitis C virus (HCV) infection, by screening and confirmatory assays
  • Hepatitis B virus (HBV) infection, by hepatitis B surface antigen (HBsAg) screening
  • Any known immunodeficiency syndrome
  • Use of anticoagulant medications
  • Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 42 days prior to or following vaccination. Immunosuppressive dose of corticosteroids is defined as greater than or equal to 10 mg prednisone equivalent per day for greater than or equal to 14 days.
  • Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to vaccination or anticipated receipt of any vaccine during the 42 days following vaccination
  • Asplenia
  • Receipt of blood products within the 6 months prior to study entry, including transfusions or immunoglobulin or anticipated receipt of any blood products or immunoglobulin during the 42 days following vaccination
  • History or serologic evidence of previous dengue virus infection or other flavivirus infection (e.g., yellow fever virus, St. Louis encephalitis virus, West Nile virus)
  • Previous receipt of a flavivirus vaccine (licensed or experimental)
  • Anticipated receipt of any investigational agent in the 42 days before or after vaccination
  • Has definite plans to travel to a dengue endemic area during the study
  • Refusal to allow storage of specimens for future research

Inclusion Criteria for Second Dose of Vaccine:

  • In good general health, as determined by physical examination and review of medical history
  • Available for the duration of the study, approximately 6 months post-vaccination
  • Willing to participate in the study as evidenced by signing the informed consent document
  • Female participants of childbearing potential must be willing to use effective contraception for the duration of the trial. More information on this criterion can be found in the protocol.

Exclusion Criteria for Second Dose of Vaccine:

  • Anaphylaxis or angioedema following the first dose of vaccine
  • Currently pregnant (as determined by positive beta-HCG test) or breastfeeding
  • Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies
  • Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the requirements of the study protocol
  • Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
  • Any significant alcohol or drug abuse in the 12 months prior to study entry which has caused medical, occupational, or family problems, as indicated by a participant's history
  • History of a severe allergic reaction or anaphylaxis
  • Severe asthma (emergency room visit or hospitalization within the 6 months prior to study entry)
  • HIV infection, by screening and confirmatory assays
  • Hepatitis C virus (HCV) infection, by screening and confirmatory assays
  • Hepatitis B virus (HBV) infection, by hepatitis B surface antigen (HBsAg) screening
  • Any known immunodeficiency syndrome
  • Use of anticoagulant medications
  • Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 42 days prior to or following vaccination. Immunosuppressive dose of corticosteroids is defined as greater than or equal to 10 mg prednisone equivalent per day for greater than or equal to 14 days.
  • Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to vaccination or anticipated receipt of any vaccine during the 42 days following vaccination
  • Asplenia
  • Receipt of blood products within the 6 months prior to study entry, including transfusions or immunoglobulin or anticipated receipt of any blood products or immunoglobulin during the 42 days following vaccination
  • Anticipated receipt of any other investigational agent in the 42 days before or after vaccination
  • Has definite plans to travel to a dengue endemic area during the study
  • Refusal to allow storage of specimens for future research

Other Treatments and Ongoing Exclusion Criteria:

The following criteria will be reviewed on Days 28 and 56 following each vaccination. If any become applicable during the study, the participant will not be included in further immunogenicity evaluations, as of the exclusionary visit. The participant will, however, be encouraged to remain in the study for safety evaluations for the duration of the study.

Ongoing Exclusion Criteria:

  • Use of any investigational drug or investigational vaccine other than the study vaccine during the 42-day period post-vaccination
  • Chronic administration (greater than or equal to 14 days) of steroids (defined as prednisone equivalent of greater than or equal to 10 mg per day), immunosuppressants, or other immune-modifying drugs initiated during the 42-day period post-vaccination (topical and nasal steroids are allowed)
  • Receipt of a licensed vaccine during the 42-day period post-vaccination
  • Receipt of immunoglobulins and/or any blood products during the 42-day period post-vaccination
  • Pregnant
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01436422
CIR 279
Yes
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Anna Durbin, MD Center for Immunization Research (CIR), Johns Hopkins School of Public Health
National Institute of Allergy and Infectious Diseases (NIAID)
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP